MedTrace Logo

Electroconvulsive Therapy Amplitude Titration

NCT04621786 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-01-11

Study results available
· View outcomes & findings →

Summary

This study is focused on advancing ECT treatment for older adults with depressive disorders by refining neuromodulation stimulus parameters to improve efficacy and cognitive safety.

Conditions

Interventions

DEVICE

Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface

The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.

Sponsors & Collaborators

  • The Zucker Hillside Hospital

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • The Mind Research Network

    collaborator OTHER

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • University of New Mexico

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-12-01
Completion
2022-12-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04621786 on ClinicalTrials.gov